Effect of niacin/laropiprant in the concentration of lipoprotein (A) in relation to the size and baseline concentrations of lipoprotein (A).

Trial Profile

Effect of niacin/laropiprant in the concentration of lipoprotein (A) in relation to the size and baseline concentrations of lipoprotein (A).

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2013

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hyperlipoproteinaemias
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Additional lead trial centres, investigators identified as reported by ClinicalTrials.gov.
    • 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01321034).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top